The importance of patient-reported outcomes in clinical trials and strategies for future optimization
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Patient-reported outcomes (PROs) can be included in clinical trials as primary or secondary endpoints and are increasingly recognized by regulators, clinicians, and patients as valuable tools to collect patient-centered data. PROs provide unique information on the impact of a medical condition and its treatment from the patient's perspective; therefore, PROs can be included in clinical trials to ensure the impact of a trial intervention is comprehensively assessed. This review first discusses examples of how PRO endpoints have added value to clinical trial interpretation. Second, it describes the problems with current practices in designing, implementing, and reporting PRO studies, and how these problems may be addressed by complying with guidance for protocol development, selecting appropriate PRO measures to match clinically motivated PRO hypotheses, minimizing the rates of avoidable missing PRO data, analyzing and interpreting PRO data, and transparently reporting PRO findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The weaRAble-PRO study administered a selection of validated PRO measures for RA in complement to bespoke digital PRO assessments—that are validated in clinical trials”
From Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000251 · Cited by 2,296
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580 · cited 2×
“21,22 The PRO endpoints led to regulatory approval of mitoxantrone for this indication and wide implementation in the clinic.”
InfluentialSelf-citationReporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension
Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & CONSORT PRO Group, F. T. (2013) · JAMA · doi:10.1001/jama.2013.879 · Cited by 1,386 · cited 2×
“This work informed the development of a CONSORT-PRO Extension (Consolidated Standards of Reporting Trials), which can be considered the minimum reporting items for PRO endpoints (primary or key secondary) in RCTs. 73 CONSORT-PRO consists of 14 items, five of which were newly developed PRO-specific reporting recommenda…”
Self-citationReducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319 · cited 1×
“However, the issue of non-reporting of PROs is emerging and requires attention, as it is unethical to waste the funding, resources, and patients’ efforts expended in PRO data collection.(71)”
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · cited 2×
“In oncology, for example, the American Society of Clinical Oncology (ASCO)(10) and European Society for Medical Oncology (ESMO)(11) have proposed standardized approaches to evaluate clinical trial results by using scores to evaluate the Magnitude of Clinical Benefit (ESMO MCB) or the Net Health Benefit (ASCO), which i…”
Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A.-W., King, M. T., and the SPIRIT-PRO Group, Hunn, A., Bottomley, A., Regnault, A., et al. (2018) · JAMA · doi:10.1001/jama.2017.21903 · Cited by 814 · cited 5×
“A second review examined the PRO content of 26 protocols of Phase III international, ovarian cancer trials published between 2000 and 2016 against a list of PRO-specific items that would eventually inform the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-PRO Extension.(29,30) Of the 26 tr…”
InfluentialSelf-citation
Research works printed but not linked: 2
- [15]Food and Drug Administration Ovarian Cancer Endpoints Workshop April 26, 2006, Meeting Summary 2006 Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Developmen-tResources/CancerDrugs/ucm094598.pdf accessed 09 August 2016 https://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm120657.pdf Accessed 14 August 2017.v
- [56]Mercieca-Bebber R Palmer MJ Brundage M Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review BMJ Open 2016 6 6 e010938 PMC4916640 27311907
Cited by
Items 401–500 of 660
Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life
Reuter, U., Heinze, A., Gendolla, A., Sieder, C., & Hentschke, C. (2024) · European Journal of Neurology · doi:10.1111/ene.16437 · Cited by 3
Outcomes Associated With Wound Care Nurses’ Practice for the Management of Venous Leg Ulcers
Monaco, D., Iovino, P., Turci, C., Marchini, R., Scarozza, S., Matranga, C., Ursino, S., & Savini, S. (2024) · Clinical Nurse Specialist · doi:10.1097/nur.0000000000000868 · Cited by 2
Patient-Reported Outcomes in Radiation Oncology
McCammack, E., & Alcorn, S. R. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.11.005 · Cited by 2
Keeley, T., Gaw, N., Ahmed, W., Alfonso‐Cristancho, R., Sousa, A. R., Forde, K., Sharp, R., Whyman, S., & Gater, A. (2024) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-024-00827-4 · Cited by 2
“Patient-reported outcome (PRO) measures are used in clinical trials to assess efficacy and ensure that treatments under development address the needs of the population that they are intended to treat [5].”
Outcome Measures of Quality of Life for People With Chronic Wounds: A Scoping Review
Dantas, J. S., Teófilo, T. J. S., da Silva, S. V., Nascimento, N. C. D., Eloy, R. A. D. L., Silva, A. C. D. O. E., & Freire, M. E. M. (2025) · Journal of Wound Ostomy and Continence Nursing · doi:10.1097/won.0000000000001170 · Cited by 2
“13-15 The value of including PROMs in clinical studies and regulatory policy making is recognized by international government bodies as important to clinical guidelines, contemporary healthcare models, health policy, and, more recently, reimbursement decisions.”
What Cachexia-Related Outcomes Are Measured in Lung Cancer Chemotherapy Clinical Trials?
Razmovski‐Naumovski, V., Tanous, A., & Valaire, R. (2025) · Cancers · doi:10.3390/cancers17142309 · Cited by 2
“…that reviewed the Australian New Zealand Clinical Trials Registry and determined that 45% of trials registered from 2005 to 2017 included PROs, whereas the trials in the Clinicaltrials.gov database determined that use of PRO endpoints were included in 27% of the trials between 2004 and 2013 [54].”
Patient-centered research in radiology: A Canadian perspective
Lee, O. N. Y., Niaghi, F., Mughli, R. A., Zulfiqar, M., Ahmad, W., Smith, S., Majeed, O., & Khosa, F. (2025) · Clinical Imaging · doi:10.1016/j.clinimag.2025.110562 · Cited by 2
Hikmet, R. G., Thorsen, L. B. J., Rose, H. K., Rossen, P. B., Baad‐Hansen, T., Nyeng, T. B., Engelmann, B. E., & Pedersen, N. A. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.103910 · Cited by 3
Guerin, G. E., Doxey, S. A., Kleinsmith, R. M., Qian, L. J., Puckett, H. D., Husband, J. B., & Cunningham, B. P. (2025) · Hand · doi:10.1177/15589447251366453 · Cited by 2
Garassino, M. C., Paz-Ares, L. G., Hui, R., Finn, C. F., Spira, A. I., Planchard, D., Özgüroğlu, M., Daniel, D. B., Vicente, D., Murakami, S., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1102 · Cited by 2
Perspectives on decisions for treatment and care in severe asthma
Winders, T. A., Maspero, J. F., Callan, L., & Al-Ahmad, M. S. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2020.100500 · Cited by 3
“An intuitive way to design RCTs with patientrelevant endpoints is to include those perspectives from the outset, from study design to outcome measures, which helps to identify whether a treatment is effectively meeting the needs of the individual.(33) Although RCTs have recently included more patient-focused aspects a…”
MethodLeong, R., Owusu, L., Tang, J., John, N., Voyer, K., Gargala, E., Daigler, B., Ma, Q., Morse, G. D., & Cha, R. (2021) · Future Virology · doi:10.2217/fvl-2020-0322 · Cited by 2
Sandhu, S. A., Angel, C. A., Campbell, K. L., Hickman, I. J., & MacLaughlin, H. L. (2021) · Nutrients · doi:10.3390/nu13103388 · Cited by 2
“The importance of evaluating PROs is well-recognised in the current literature given their value in informing patientcentered care [93].”
Bhandari, N. R., Kamel, M. H., Kent, E. E., McAdam‐Marx, C., Ounpraseuth, S., Tilford, J. M., & Payakachat, N. (2021) · Healthcare · doi:10.3390/healthcare9101344 · Cited by 2
Tomim, D. H., Lenhani, B. E., Nogueira, L. D. A., Vogt, T. N., Silva, L. D. S., Mantovani, M. D. F., Guimarães, P. R. B., & Kalinke, L. P. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1346 · Cited by 2
“In addition, questionnaires of this nature can provide pertinent information about the patient’s real situation and provide a survival forecast based on their answers [26].”
BackgroundConduit, C., Mak, B., Qu, W., Lulio, J. D., Burder, R., Bressel, M., Cusick, T., Dhillon, H. M., Lourenço, R. D. A., Underhill, C. R., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221092486 · Cited by 2
Bang, G., Kang, D., & Cho, J. (2022) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2022.32.1.74 · Cited by 4
Leveraging the regulatory framework to facilitate drug development in Parkinson's disease
Müller, M. L. T. M., & Stephenson, D. T. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00015-1 · Cited by 2
4-DOMAIN SPORTS PROM TRANSLATION AND CULTURAL ADAPTATION INTO PORTUGUESE
de Toledo, A. H. N., Ferreira, D. M., de Vasconcelos, R. A., Filho, M. F., Pedrinelli, A., & Piedade, S. R. (2023) · Revista Brasileira de Medicina do Esporte · doi:10.1590/1517-8692202430022022_0562i · Cited by 2
Gater, A., Tolley, C., Williams‐Hall, R., Trennery, C., Bradley, H., Sikirica, M. V., Nelsen, L. M., Sousa, A. R., Bratton, D. J., Chan, R. H., et al. (2023) · OTO Open · doi:10.1002/oto2.84 · Cited by 2
Gassmann, P. V. (2023) · Oftalmología clínica y experimental. · doi:10.70313/2718.7446.v16.n01.207 · Cited by 2
Mikhail, J., Hofstetter, L., Côté, P., Tricco, A. C., Pagé, I., & Hincapié, C. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057677 · Cited by 2
Dulko, D. (2020) · Worldviews on Evidence-Based Nursing · doi:10.1111/wvn.12441 · Cited by 2
Rajkumar, J. R., Jetter, N., Samuels, K., & Schwartz, A. (2021) · Pediatric Dermatology · doi:10.1111/pde.14611 · Cited by 2
Looking beyond the obvious: the importance of outcomes and outcomes measures in trigeminal neuralgia
Nova, C. V., Ríordáin, R. N., Baker, S. R., & Zakrzewska, J. M. (2021) · Pain · doi:10.1097/j.pain.0000000000002349 · Cited by 2
Fisher, L., Polonsky, W. H., Bowyer, V., & Hessler, D. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107533 · Cited by 2
Majercak, K. R., Perfetto, E. M., & Villalonga-Olives, E. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00411-8 · Cited by 1
Quality of Life in Women with Ovarian Cancer
Campbell, R., King, M. T., Lee, Y. C., Mileshkin, L., Tait, M.-A., & Rutherford, C. (2022) · Springer eBooks · doi:10.1007/978-3-031-09169-8_13 · Cited by 1
Self-citationDeMuro, C., Mayorga, M. A., Ruiz‐Guiñazú, J., Trudel, G. C., Fehnel, S. E., McQuarrie, K., Chan, E. K. H., & Katz, E. G. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00542-6 · Cited by 1
Hughes, G. K., Sutterfield, B., Anderson, R. M., Streck, S., Hillman, C., Shepard, S., Wise, A., Ottwell, R., Hartwell, M. L., & Vassar, M. B. (2023) · Psychiatric Quarterly · doi:10.1007/s11126-023-10017-y · Cited by 2
“The benefits of PROs have augmented their use in randomized controlled trials (RCTs); researchers and clinicians nest PRO measures within trials to clarify treatment effectiveness and increase the understanding of the patient’s experience [8].”
BackgroundGutiérrez‐Ibarluzea, I., Bolaños, N., Geißler, J., Gorgoni, G., Lumley, T., Mikhael, J. R., Milagre, T. H., & Poppel, H. V. (2023) · Journal of Oncology Research and Therapy · doi:10.29011/2574-710x.10181 · Cited by 6
“Firstly, tools used for PROs collection may be considered too generic and may not capture outcomes that are specific to the disease, staging or treatment characteristics [43-46].”
MethodDostarlimab as a promising immunotherapy for endometrial cancer treatment – literature review
Derlatka, K., Tasior, J., Kulczycka, M., Pasieczna, W., & Prendecka, M. (2023) · Journal of Pre-Clinical and Clinical Research · doi:10.26444/jpccr/172403 · Cited by 1
Zhang, J., Zhang, M., Xu, C., Tian, J., Yang, D., & Wang, B. (2024) · Advances in Skin & Wound Care · doi:10.1097/asw.0000000000000196 · Cited by 1
Ayasse, N. D., & Coon, C. D. (2024) · Quality of Life Research · doi:10.1007/s11136-024-03873-z · Cited by 2
“A lengthy measure may produce less reliable and valid data or contribute to higher rates of missing data [14, 27].”
Thompson, R., Fors, M., Kammerlind, A.-S. C., Tingström, P., Abbott, A. D., & Johansson, K. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316806 · Cited by 1
“Pain intensity is chosen as a primary outcome for this study as it is a core outcome measure for intervention studies on pain [51, 52].”
Alahmadi, S., Herrera, D. B., Heron, M. J., Gomez-Rexrode, A. E., Perla, K. M. R., Soto, E., Ghanem, D., Shafiq, B., & Mundy, L. R. (2025) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000006511 · Cited by 1
Marques, E. A., Caliskan, O., Brooke-Wavell, K. S. F., & Folland, J. P. (2025) · Maturitas · doi:10.1016/j.maturitas.2025.108246 · Cited by 2
Reflections on the Optimal Use of eDiaries for Data Collection in Vaccine Clinical Trials
Nukala, U., Cho, S., Sahu, A., Zhou, J., Steele, W. R., Whitaker, B. I., Chang, S. H., & Ezzeldin, H. (2025) · Journal of Medical Internet Research · doi:10.2196/66971 · Cited by 1
“The use of PROs in clinical trials to inform decision-making, cost-effectiveness analysis, clinical guidelines, and health policy has shown a clear increase over time [2].”
Steinbrink, G. M., Danielson, T., Martinez, J., Patnode, J. M., Swartz, A. M., & Strath, S. J. (2025) · Healthcare · doi:10.3390/healthcare13080905 · Cited by 2
“…of this study is its use of not only objective PF outcomes but also self-reported PF outcomes, which are increasingly recognized as valuable patient data, as they provide unique information regarding a patient’s condition and abilities not otherwise captured by more objective PF outcomes [55].”
He, W., Jing, F., Gao, Y., Yi, H., Li, M., You, J., Shen, Y., Wu, Y., Kang, P., Yu, Z. H., et al. (2025) · Psycho-Oncology · doi:10.1002/pon.70152 · Cited by 2
“The shift toward value‐based healthcare has promoted a more patient‐centered approach in oncology research [29], as reflected by the growing incorporation of PROs endpoints in cancer studies [30].”
Nööjd, M., Elmasry, M., & Steinvall, I. (2025) · International Wound Journal · doi:10.1111/iwj.70197 · Cited by 1
“An excessive focus on clinically measurable predictors, also known as surrogates, risks jeopardising patient care if they are allowed to prevail without regard to the outcome measures pri-oritised by patients [13, 14].”
Sun, Y., Chen, S., Neyret, P., Hutchinson, M. R., Migliorini, F., Maffulli, N., Górios, C., & Piedade, S. R. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-05882-1 · Cited by 1
“[22, 23] The apparent void of PROM tailored to assess athletes and regular sports practitioners [11] has become the starting point develop a PROM tailored for Sports Medicine – the 4-Domain Sports PROM.”
Figueroa, Ú., Sanhueza, D., Grimoldi, M., Mackenna, E. C., Selman, R., Machuca, E., Jarry, C., Escalona, G., Crovari, F. J., Quezada, N., et al. (2025) · Journal of Laparoendoscopic & Advanced Surgical Techniques · doi:10.1177/10926429251359745 · Cited by 2
“30,31 Therefore, this study aims to take a fi rst step in analyzing the relevance of formal training through the BSC in achieving higher standards of quality care through self-reports from course trainees.”
Establishing ovarian toxicity assessment in oncology trials
Martin, F. C., & Cui, W. (2025) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2025.102642 · Cited by 1
Krajnak, S., Battista, M. J., Shehaj, I., Heimes, A.-S., Schinköthe, T., Brenner, W., Hasenburg, A., & Schmidt, M. (2025) · Oncology Research and Treatment · doi:10.1159/000547766 · Cited by 1
“PRO can be included in clinical trials to enhance the understanding of treatment and disease impact on HRQoL [15].”
Shorey, C., Williamson, P. R., & Dodd, S. R. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095190 · Cited by 1
“9 For Bronchiec-tasis, the study recommended that the top five outcomes should be prioritised for uptake, with the remaining outcomes considered on a case- by-case basis.”
Yarza, R., Barquín, A., Caruso, G., Guedes, H., Kountouri, M., Lorenzo, J. M. E., Bogani, G., Coens, C., Herrera, F. G., Kroep, J. R., et al. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.102115 · Cited by 1
Forshall, G., Budds, K., Fisher, V., Jha, S., Gray, T. G., Doumouchtsis, S. K., Bagnall, A., & Jones, G. L. (2025) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.18355 · Cited by 1
“These measures provide rich data that cannot be obtained from conventional consultations alone [3], and assess a range of subjective outcomes from urinary, bowel and vaginal symptoms to sexual function, pain and discomfort, emotional wellbeing and re-lated impacts on HRQL [4, 5].”
Patient‐reported outcome measures in prostate research: a scoping review
Young, G., Walsh, E. I., Lane, J. A., Donovan, J., Drake, M. J., Pedder, H., & Metcalfe, C. D. (2025) · British Journal of Urology · doi:10.1111/bju.70022 · Cited by 1
“The addition of PROMs, in RCTs, has gained momentum during the past few decades and is an evolving fi eld [1,2].”
Quality of Life and Mental Health Problems in Pediatric Cardiac Arrest Survivors
Schwartz, T., Weidenbach, M., Daehnert, I., Paech, C., & Markel, F. (2025) · Children · doi:10.3390/children12101397 · Cited by 2
“Standardized questionnaires are utilized to evaluate patient-related health, wherein patients self-report their health status, quality of life, or treatment outcomes [9].”
Kearney, M., Macmillan, T., Poritz, J., Schreiber-Gosche, S., & Musat, M. G. (2025) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2025.09.016 · Cited by 1
Girges, C., Vijiaratnam, N., King, A., Auld, G., McComish, R., Chowdhury, K., Ambler, G., Maclagan, K., Limousin, P. D., Athauda, D. S., et al. (2025) · Clinical Trials · doi:10.1177/17407745251387571 · Cited by 1
“19 Depression may be a psychological reaction to a diagnosis or to the presence of motor/non-motor disability, or may be a manifestation of the neurodegenerative process itself.”
Effect of music therapy on patient experience in gastrointestinal endoscopy: a scoping review
Hearn, J., & Carpentier, S. M. (2025) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwaf034 · Cited by 1
Stetter, B. J., Dully, J., Stief, F., Holder, J., Steingrebe, H., Zaucke, F., Sell, S., van Drongelen, S., & Stein, T. (2025) · Arthritis Research & Therapy · doi:10.1186/s13075-025-03709-2 · Cited by 1
“When quality of life becomes severely affected, total hip replacement is the primary surgical treatment option [5].”
Alanazi, M., Parent, É., Gross, D. P., Bettany‐Saltikov, J., Ganci, A., Southon, S. H., & Lin, A. (2026) · Children · doi:10.3390/children13010087 · Cited by 1
Conceptualising the experience of having TB: a global qualitative study
Oberdhan, D., Hill, M., Gillman, A., McGale, N., Dandy, J., Abdullaev, T., & Dara, M. (2026) · IJTLD OPEN · doi:10.5588/ijtldopen.25.0112 · Cited by 1
Varesio, C., Pasca, L., Zanaboni, M. P., Bertoli, S., Brancaccio, C., Camerini, A., Celario, M., Granata, T., Grumi, S., Lodi, A., et al. (2026) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2026.01.002 · Cited by 1
Daszkiewicz, M., Prill, R., Lettner, J., Urban, N., Andrzejczak, K., Witkowski, W., Starzyk, K., Hunter-Giordano, A. O., Reichert, P., & Królikowska, A. (2026) · Knee Surgery Sports Traumatology Arthroscopy · doi:10.1002/ksa.70311 · Cited by 4
Conducting clinical trials in supportive and palliative oncology: challenges and opportunities
Hui, D., & Bruera, E. (2026) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001216 · Cited by 1
Arriola, E., Casarini, I., Özgüroğlu, M., Huang, M., Takahashi, T., Lai, X., Goto, K., Maneenil, K., Lee, K. H., Cobo, M., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116744 · Cited by 1
Riaz, S., Khuda, F., Khan, A., Jan, A., Ibenmoussa, S., Alotaibi, G., Ali, S. S., & Albabtain, B. A. (2026) · Annals of General Psychiatry · doi:10.1186/s12991-026-00644-7 · Cited by 1
“PRO-AEs identify adverse effects earlier than clinician reports [24, 25].”
The Importance of Basic Research for Physiotherapy Science
Poehlmann, J., Batista, J. P., Butry, L., Carvalho, G. F., Frankenstein, T., Haueise, A., Heise, K.-F., Kapitza, C., Luedtke, K., Lübke, L., et al. (2026) · physioscience · doi:10.1055/a-2725-5443 · Cited by 1
“The focus is still predominantly on clinical studies that primarily evaluate the effect of physiotherapy interventions on patient-centred outcomes – a research approach that undoubtedly has direct relevance for therapeutic decision-making [5].”
Gama-Castro, A., Ferrão-Mendes, A., Rodrigues, R., Figueiredo, I., Bragança, F., Laiginhas, R., Cunha, A. M., Lume, M., da Silva, R. M., & Carneiro, Â. (2026) · Acta Médica Portuguesa · doi:10.20344/amp.24246 · Cited by 1
Saab, M. M., Hegarty, J. M., Gleeson, J. P., Murphy, D., McHugh, S., Shiely, F., Murphy, A., Kirby, A., Korfage, I. J., Terhaard, S., et al. (2026) · Andrology · doi:10.1111/andr.70263 · Cited by 2
Górecki, S., Tatka, A., & Osmola, M. (2026) · Cancers · doi:10.3390/cancers18121905 · Cited by 1
“Reporting treatment toxicities, as well as quality of life, nowadays usually with PROS, is an important endpoint of clinical trials [1].”
Hu, T., Lupton, L. L., Yehoshua, A., Cappelleri, J. C., Gavaghan, M. B., Welch, V. L., Lopez, S. M. C., Brathwaite, R., Fusco, M. D., & Sun, X. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13950-y · Cited by 1
“These data provide a comprehensive view of symptom burden and recovery patterns revealing dimensions often missed through clinical indicators alone [45].”
Predictors of patient-reported health following cardiac surgery
Jarmoszewicz, K., Nowicka‐Sauer, K., Wera, K., Meslin-Kuźniak, A., Beta, S., & Pietrzykowska, M. (2021) · The Journal of Cardiovascular Surgery · doi:10.23736/s0021-9509.21.11452-1 · Cited by 1
Cecil, E., Cheng, Z., Han, P., & Quon, H. (2021) · Clinical journal of oncology nursing · doi:10.1188/21.cjon.e44-e49 · Cited by 1
Why Are Real Patient Outcomes Important?
Galandiuk, S. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002632 · Cited by 1
Ju’subaidi, J., & Mahmudin, A. S. (2023) · Cendekia Jurnal Kependidikan dan Kemasyarakatan · doi:10.21154/cendekia.v21i1.5965 · Cited by 1
Age‐related change in gait efficacy and predictors of its decline: A 3‐year longitudinal study
Sato, Y., Taniguchi, M., Fukumoto, Y., Okada, S., Wang, Z., Nakazato, K., Niiya, N., Yamada, Y., Kimura, M., & Ichihashi, N. (2023) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14767 · Cited by 1
ÖZCAN, E. K., Karabulut, M., Karakoç, K., & Müjdeci, B. (2024) · Journal of Aging and Physical Activity · doi:10.1123/japa.2023-0267 · Cited by 1
Rosenberg, M., Rodriguez, R., Grant, S., Miguel, A. S., Lee, J. O., & Rosenberg, L. (2024) · Seminars in Plastic Surgery · doi:10.1055/s-0044-1782650 · Cited by 4
“53 It provides insight into how disability and disease affect youth and adults in multiple health domains.”
BackgroundShahbaz, M., Harding, J. E., Milne, B. J., Walters, A. G. B., von Randow, M., Gamble, G. D., & for the ANCHOR Study Group (2024) · PLoS ONE · doi:10.1371/journal.pone.0308414 · Cited by 2
El-Jawahri, A. R., Waterman, B. L., Enguidanos, S. M., Gibbs, L., Navarro, V. J., Olsen, M. K., Temel, J. S., Totten, A. M., & Grudzen, C. R. (2024) · Medical Care · doi:10.1097/mlr.0000000000002042 · Cited by 1
Fathima, P., Pan, E., Marsh, J. A., Newall, N., Meares, T., McLeod, C., Shanthikumar, S., Jaffé, A., Tai, A., Ward, N., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108080 · Cited by 1
External validation of the polymyalgia rheumatica impact scale: a prospective cohort study
Moreel, L., Doumen, M., Betrains, A., Langhe, E. D., Blockmans, D., & Vanderschueren, S. (2025) · Rheumatology Advances in Practice · doi:10.1093/rap/rkaf046 · Cited by 2
Retzer, A., Al-Jilaihawi, S., Bailey, S., Buenger, V., Damery, S. L., Darlington, A., Diezi, M., Peipert, J. D., Roydhouse, J. K., & Reeve, B. B. (2025) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2025.100232 · Cited by 2
Mundhra, S. K., Sharma, R. K., & Kochhar, R. K. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01848-7 · Cited by 1
“PROs encompass disease symptoms, treat-ment side effects, functional outcomes or multidimensional measures such as health-related quality of life (HRQOL) [1].”
Therrien, F., Chokka, P. R., Habert, J., Ismail, Z., McIntyre, R. S., Dine, J. L., Brown, T. M., Zhang, Z., MacKenzie, E. M., & Ward, C. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2558140 · Cited by 1
Health-related quality of Life Instrument in Neuromuscular Disorders
Kwon, O. (2021) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2021.2.24 · Cited by 1
“PROs는 환자가 보고하는 1) 질환의 증상이나 통증, 피 로, 불안 등의 질환의 증상이나 치료의 부작용; 2) 신체적, 성적, 사회 적, 정서적 그리고 인지기능 등 기능적 결과; 3) HRQoL이나 health utility를 포괄하는 다면적 개념 구조이다.(2) 이는 흔히 특정 질환의 중증도, 치료 경과 등에만 관심을 가지는 임상 의학의 관점보다 훨씬 더 광범위한 영역에서 질환이 환자에 미치는 영향을 평가한다.”
King, M. T., Tait, M.-A., Campbell, R., Müller, F., Rutherford, C., Beckmore, C., Chima, S., Langbecker, D., Shaw, J., & Mercieca‐Bebber, R. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03127-w · Cited by 2
“It is therefore concerning that oncology trialists and principal investigators have expressed skepticism about PROs due to their subjectivity and focus on survival outcomes, relegating PROs to a relatively low position in the trial outcome hierarchy [28, 29].”
Self-citationNeoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma
Haas, N. B., Shevach, J. W., Davis, I. D., Eisen, T. G., Gross-Gupil, M., Kapoor, A., Master, V. A., Ryan, C. W., & Schimdinger, M. (2022) · Société Internationale d’Urologie Journal · doi:10.48083/vsqg7437 · Cited by 1
Teng, T., Barco, T. L., Marie, E., Hallet, A., Brambilla, I., Flege, S., D’Onofrio, G., Chémaly, N., Kuchenbuch, M., & Nabbout, R. (2021) · Research Square · doi:10.21203/rs.3.rs-293272/v1 · Cited by 1
“PROs can be used to determine affected individual’s experience particularly concerning improvement or aggravation of subjective symptoms, to stratify participants, to re ne clinical trial design and to illustrate the risk-bene t balance allowing to choose the personalized better treatment [34].”
Editorial: Maintaining the Integrity of PROMs in Research and Practice
Kim, M., Fong, J., Pusic, A. L., Fischer, J. P., Mehrara, B. J., & Nelson, J. A. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13394-7 · Cited by 1
Omar, M. T., Al-Dhwayan, N., Al-Karni, M. A. T., Ajarim, D. S., Idreess, M. J. N., & Gwada, R. F. M. (2023) · Research Square · doi:10.21203/rs.3.rs-2793187/v1 · Cited by 1
Bakker, J. P., McClenahan, S. J., Fromy, P., Turner, S., Peterson, B., Vandendriessche, B., & Goldsack, J. C. (2024) · doi:10.2196/preprints.58956 · Cited by 1
Doğan, U. (2024) · Preprints.org · doi:10.20944/preprints202408.1814.v1
Nikolovski, J., Kim, B., Morton, R. L., Mercieca‐Bebber, R., Lévesque, J., Tinsley, M., Sutherland, K., Rossiter, B., Fagan, M., Hartas, G., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5300049/v1 · Cited by 1
Self-citationGout: Patients, Medicine and Society
Janssen, C. A. (2019) · doi:10.3990/1.9789036548113
Inclusion of Patient-Reported Outcomes in Clinical Trials
Zhang, L. M., Sturgeon, C., Yang, A. D., & Merkow, R. P. (2020) · Success in academic surgery · doi:10.1007/978-3-030-35488-6_19 · Cited by 1
Borg, S. (2021) · Linköping University medical dissertations · doi:10.3384/diss.diva-178235
Brain morphology, survival and patient-reported outcomes after cranial radiotherapy
Nagtegaal, S. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/939
Loubert, A., Regnault, A., Sebille, V., & Hardouin, J.-B. (2021) · Research Square · doi:10.21203/rs.3.rs-1182025/v1
Hidaka, T., Sato, S., Endo, S., Kasuga, H., Masuishi, Y., Kakamu, T., & Fukushima, T. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031671
Monmousseau, F., Mulot, L., Rüsch, E., Picon, L., Laharie, D., Fotsing, G., Gargot, D., Charpentier, C., Buisson, A., Trang, C., et al. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.2025419
Ravn, S., Thaysen, H. V., Seibæk, L., Verwaal, V. J., & Iversen, L. H. (2020) · doi:10.2196/preprints.18397
Ezendu, K., & Ali, A. A. (2021) · doi:10.2196/preprints.32397
Frailty and quality of life in older adults with cancer
Scheepers, E. R. M. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/495
Meng, Z. (2022) · Wiley eBooks · doi:10.1002/9781119913276.ch9
Metadata
- Authors
- Mercieca-Bebber, R., King, M. T., Calvert, M. J., Stockler, M. R., & Friedlander, M.
- Affiliations
- The University of Sydney (AU)
- National Institute for Health and Care Research (GB)
- Corresponding author
- Friedlander, Michael
- Venue
- Patient Related Outcome Measures
- Publisher
- Informa UK Limited
- Published
- 2018-11
- Volume
- Volume 9
- Pages
- 353-367
- ISSN
- 1179-271X (ISSN-L)
- PMC
- PMC6219423
- OpenAlex
- W2899320385
- Cited by
- 659
- References
- 73
- Citations by year
- 2026: 77 · 2025: 129 · 2024: 138 · 2023: 88 · 2022: 85 · 2021: 75 · 2020: 54 · 2019: 12
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Related Outcome Measures (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- University Hospitals Birmingham NHS Foundation Trust
- Australian Government
- National Institute for Health and Care Research
- University of Birmingham
- Cancer Australia
- Surgical Reconstruction and Microbiology Research Centre
- National Health and Medical Research Council
- Birmingham Biomedical Research Centre
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- patient-reported outcomes, clinical trial endpoints, missing data, protocol design, patient-centered outcomes, regulatory guidelines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.